Inhibition of Angiogenesis: Thalidomide or Low-Molecular-Weight Heparin?
- 20 March 2005
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (9) , 2113
- https://doi.org/10.1200/jco.2005.05.245
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancerJournal of Thrombosis and Haemostasis, 2004
- Intraperitoneal immunotherapy of peritoneal carcinomatosis from solid tumors by trifunctional antibodiesJournal of Clinical Oncology, 2004
- Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)Journal of Clinical Oncology, 2004
- Blood Vessels are Regulators of Growth, Diagnostic Markers and Therapeutic Targets in Prostate CancerScandinavian Journal of Urology and Nephrology, 2001
- Angiogenesis in urological malignancy: prognostic indicator and therapeutic targetBJU International, 1999
- A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin FragmentScience, 1985
- Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of CortisoneScience, 1983